Relapsing Acute Myeloid Leukemia With A Susceptible Idh1 Mutation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for relapsing acute myeloid leukemia with a susceptible idh1 mutation. 14 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
14
Active US patents
55/100
Avg vulnerability
—
Annual revenue covered

Originators in Relapsing Acute Myeloid Leukemia With A Susceptible Idh1 Mutation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Rigel Pharms 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating relapsing acute myeloid leukemia with a susceptible idh1 mutation. Each bar = one year. Y-axis scaled to peak year (9 patents).

5
35
9
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Rezlidhia
OLUTASIDENIB
 Rigel Pharms 14 55 — 2035-09-18

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12275715 Rezlidhia method of use 75 2035-09-18
9834539 Rezlidhia method of use 70 2035-09-18
11013733 Rezlidhia method of use 70 2039-05-16
11497743 Rezlidhia method of use 70 2039-05-16
11013734 Rezlidhia method of use 70 2039-05-16
11376246 Rezlidhia method of use 70 2039-05-16
11738018 Rezlidhia method of use 70 2039-07-17
10550098 Rezlidhia formulation 50 2035-09-18
10414752 Rezlidhia formulation 50 2035-09-18
11498913 Rezlidhia formulation 50 2035-09-18

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10532047 Rezlidhia composition of matter 12 2039-05-16
12053463 Rezlidhia composition of matter 17 2039-05-16
11723905 Rezlidhia formulation 50 2039-11-12
10959994 Rezlidhia formulation 50 2039-05-16
10550098 Rezlidhia formulation 50 2035-09-18
10414752 Rezlidhia formulation 50 2035-09-18
11498913 Rezlidhia formulation 50 2035-09-18
11738018 Rezlidhia method of use 70 2039-07-17
11013734 Rezlidhia method of use 70 2039-05-16
11376246 Rezlidhia method of use 70 2039-05-16

Related